Investigational drug · Phase 3
STN1013800
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Blepharoptosis.
Phase 3Last checked: Nov 20, 2026Latest source record: May 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "STN1013800"
First trial start
2024
Oct 22, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "STN1013800", any sponsor or status.
Conditions studied
As listed on its trial records.
- Blepharoptosis
Largest trials
Live from ClinicalTrials.gov: studies naming "STN1013800" as an intervention, largest first.
- LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.Pivotal-lookingRecruiting
Santen SASIndustry
NCT06514612 · 234 participants (planned) · Start Dec 30, 2024 · Primary completion Aug 1, 2026
Drug: STN1013800 (0.1% Oxymetazoline Hydrochloride) eye drops in single dose containers · For: Acquired Blepharophimosis
Sites: Pardubice, Czechia; Pilsen, Czechia; Prague, Czechia · 36 sites in all
- A Study in Chinese Patients With Acquired BlepharoptosisPivotal-lookingRecruiting
Santen Pharmaceutical Co., Ltd.Industry
NCT06683651 · 180 participants (planned) · Start Oct 22, 2024 · Primary completion Jun 2026
Drug: STN1013800 ophthalmic solution; STN1013800 ophthalmic solution Liquid Base, without STN1013800 · For: Blepharoptosis
Sites: Hefei, China; Beijing, China; Shantou, China · 23 sites in all
Santen Pharmaceutical Co., Ltd.Industry
NCT06911216 · 8 participants · Start Mar 17, 2025 · Primary completion Apr 7, 2025
Drug: STN1013800 ophthalmic solution · For: Blepharoptosis
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.